PT - JOURNAL ARTICLE AU - Dennis, Andrea AU - Wamil, Malgorzata AU - Kapur, Sandeep AU - Alberts, Johann AU - Badley, Andrew D. AU - Decker, Gustav Anton AU - Rizza, Stacey A AU - Banerjee, Rajarshi AU - Banerjee, Amitava AU - , TI - Multi-organ impairment in low-risk individuals with long COVID AID - 10.1101/2020.10.14.20212555 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.14.20212555 4099 - http://medrxiv.org/content/early/2020/10/16/2020.10.14.20212555.short 4100 - http://medrxiv.org/content/early/2020/10/16/2020.10.14.20212555.full AB - Background Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection has disproportionately affected older individuals and those with underlying medical conditions. Research has focused on short-term outcomes in hospital, and single organ involvement. Consequently, impact of long COVID (persistent symptoms three months post-infection) across multiple organs in low-risk individuals is yet to be assessed.Methods An ongoing prospective, longitudinal, two-centre, observational study was performed in individuals symptomatic after recovery from acute SARS-CoV-2 infection. Symptoms and organ function (heart, lungs, kidneys, liver, pancreas, spleen) were assessed by standardised questionnaires (EQ-5D-5L, Dyspnoea-12), blood investigations and quantitative magnetic resonance imaging, defining single and multi-organ impairment by consensus definitions.Findings Between April and September 2020, 201 individuals (mean age 44 (SD 11.0) years, 70% female, 87% white, 31% healthcare workers) completed assessments following SARS-CoV-2 infection (median 140, IQR 105-160 days after initial symptoms). The prevalence of pre-existing conditions (obesity: 20%, hypertension: 6%; diabetes: 2%; heart disease: 4%) was low, and only 18% of individuals had been hospitalised with COVID-19. Fatigue (98%), muscle aches (88%), breathlessness (87%), and headaches (83%) were the most frequently reported symptoms. Ongoing cardiorespiratory (92%) and gastrointestinal (73%) symptoms were common, and 42% of individuals had ten or more symptoms.There was evidence of mild organ impairment in heart (32%), lungs (33%), kidneys (12%), liver (10%), pancreas (17%), and spleen (6%). Single (66%) and multi-organ (25%) impairment was observed, and was significantly associated with risk of prior COVID-19 hospitalisation (p<0.05).Interpretation In a young, low-risk population with ongoing symptoms, almost 70% of individuals have impairment in one or more organs four months after initial symptoms of SARS-CoV-2 infection. There are implications not only for burden of long COVID but also public health approaches which have assumed low risk in young people with no comorbidities.Funding This work was supported by the UK’s National Consortium of Intelligent Medical Imaging through the Industry Strategy Challenge Fund, Innovate UK Grant 104688, and also through the European Union’s Horizon 2020 research and innovation programme under grant agreement No 719445.Competing Interest StatementRB and AB are CEO and Head of Biomarker Science respectively at Perspectum. AB has received unrelated research grants from Astra Zeneca.Clinical TrialNCT04369807Funding StatementThis work was supported by the UK National Consortium of Intelligent Medical Imaging through the Industry Strategy Challenge Fund, Innovate UK Grant 104688, and also through the European Union Horizon 2020 research and innovation programme under grant agreement No 719445.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Berkshire B ethics committee,UK (20/SC/0185)-ethical approval given.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData relating to this study is not available while the study is ongoing but will be made available by contacting the study team after recruitment and completion of follow-up.